Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

Open Vet J. 2021; 11(1): 154-159


THERAPEUTIC EQUIVALENCE OF IVERMECTIN 1 % AND TWO NOVEL FORMULATIONS COMBINED OF IVERMECTIN 1% + FLUAZURON 12.5 % FOR THE CONTROL OF RHIPICEPHALUS (BOOPHILUS) MICROPLUS IN URUGUAY

Diego Robaina, Silvana Alvariza, Gonzalo Suárez.




Abstract
Cited by 0 Articles

Background: Novel combinations of ivermectin and fluazuron are presented as an alternative for cattle tick control. Applying combination of drugs with the aim to affect different stages of the parasite´s life cycle is stablished as a potential measure to achieve control of cattle tick.
Aim: To determine therapeutic equivalence between two novel formulations of ivermectin 1% combined with fluazuron 12.5 % tested on bovines naturally infested with Rhipicephalus (Boophilus) microplus.
Methods: Forty adult beef cattle were randomized into four groups (n = 10): IVM [ivermectin 1% (0.2 mg/kg)] and combinations groups A and B [ivermectin 1% (0.2 mg/kg) + fluazuron 12.5% (2.5 mg/kg), each] and Control [untreated]). During 49 days the presence of ticks was ranked as null, low, medium and high; a cumulative link model was adjusted to evaluate treatment response. Results: Although all groups had some animals with presence of ticks until day 27, on day 14 IVM (OR 0.013, CI95%: 0.001 to 0.014, p

Key words: Bovine, Drug combination, Ectoparasites, Tick






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.